CYP39A1: A Potential Drug Target and Biomarker (G51302)

Target Name: CYP39A1

NCBI ID: G51302

CYP39A1

Other Name(s): CYP39A1 variant 1 | cytochrome P450 family 39 subfamily A member 1 | Cytochrome P450 family 39 subfamily A member 1, transcript variant 1 | cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1 | cytochrome P450, family 39, subfamily A, polypeptide 1 | CYP39A1 oxysterol 7a-hydroxylase | 24-hydroxycholesterol 7-alpha-hydroxylase (isoform 1) | CP39A_HUMAN | hCYP39A1 | Oxysterol 7alpha-hydroxylase | Cytochrome P450 39A1 | Cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1 | 24-hydroxycholesterol 7alpha-monooxygenase | Oxysterol 7-alpha-hydroxylase | 24-hydroxycholesterol 7-alpha-hydroxylase

CYP39A1: A Potential Drug Target and Biomarker

CYP39A1 (CYP39A1 variant 1) is a gene that encodes for a protein known as CYP39A1. This protein is an enzyme that is primarily found on the surface of cells in the body, including liver, lung, and blood cells. It is responsible for metabolizing a wide variety of drugs, including many statins, which are used to treat conditions such as heart disease and high cholesterol.

CYP39A1 has been identified as a potential drug target for several reasons. First, it is an enzyme that is involved in the metabolism of a wide variety of drugs, which means that it could be a useful target for drugs that are used to treat a wide range of conditions. Second, studies have shown that variants of the CYP39A1 gene have been associated with an increased risk of certain health problems, such as heart disease and diabetes. This suggests that targeting CYP39A1 could be a way to prevent or treat these conditions.

In addition to its potential as a drug target, CYP39A1 is also a potential biomarker for several diseases. For example, studies have shown that levels of CYP39A1 have been elevated in the blood of people with certain types of cancer, which suggests that it may be a useful indicator of disease status in these cases. Additionally, CYP39A1 has been shown to be involved in the regulation of several cellular processes, including cell signaling and inflammation. This suggests that it may be a useful target for drugs that are used to treat or to prevent a wide range of diseases.

It is worth noting that while CYP39A1 is an interesting target for drug research, it is important to remember that it is just one potential target. Many other genes have also been identified as potential drug targets, and it is likely that new ones will be discovered in the future. Additionally, it is important to consider the potential side effects and risks associated with targeting CYP39A1, as well as other potential drug targets.

Overall, CYP39A1 is a gene that has the potential to be a drug target or biomarker for a wide range of diseases. While more research is needed to fully understand its role and potential, it is an important area of 鈥嬧?媟esearch that could have significant implications for the treatment of many diseases.

Protein Name: Cytochrome P450 Family 39 Subfamily A Member 1

Functions: A cytochrome P450 monooxygenase involved in neural cholesterol clearance through bile acid synthesis (PubMed:25201972, PubMed:10748047). Catalyzes 7-alpha hydroxylation of (24S)-hydroxycholesterol, a neural oxysterol that is metabolized to bile acids in the liver (PubMed:25201972, PubMed:10748047). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25201972, PubMed:10748047)

The "CYP39A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP39A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets